JP2023519974A5 - - Google Patents
Info
- Publication number
- JP2023519974A5 JP2023519974A5 JP2022559578A JP2022559578A JP2023519974A5 JP 2023519974 A5 JP2023519974 A5 JP 2023519974A5 JP 2022559578 A JP2022559578 A JP 2022559578A JP 2022559578 A JP2022559578 A JP 2022559578A JP 2023519974 A5 JP2023519974 A5 JP 2023519974A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- formula
- conjugate
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025096813A JP2025128284A (ja) | 2020-03-31 | 2025-06-10 | ｎｅｏＤｅｇｒａｄｅｒコンジュゲート |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003179P | 2020-03-31 | 2020-03-31 | |
| US63/003,179 | 2020-03-31 | ||
| US202063067967P | 2020-08-20 | 2020-08-20 | |
| US63/067,967 | 2020-08-20 | ||
| PCT/IB2021/052713 WO2021198965A1 (en) | 2020-03-31 | 2021-03-31 | Neodegrader conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025096813A Division JP2025128284A (ja) | 2020-03-31 | 2025-06-10 | ｎｅｏＤｅｇｒａｄｅｒコンジュゲート |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519974A JP2023519974A (ja) | 2023-05-15 |
| JP2023519974A5 true JP2023519974A5 (https=) | 2024-01-11 |
Family
ID=77928113
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559578A Pending JP2023519974A (ja) | 2020-03-31 | 2021-03-31 | ｎｅｏＤｅｇｒａｄｅｒコンジュゲート |
| JP2025096813A Pending JP2025128284A (ja) | 2020-03-31 | 2025-06-10 | ｎｅｏＤｅｇｒａｄｅｒコンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025096813A Pending JP2025128284A (ja) | 2020-03-31 | 2025-06-10 | ｎｅｏＤｅｇｒａｄｅｒコンジュゲート |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230338564A1 (https=) |
| EP (1) | EP4126067A4 (https=) |
| JP (2) | JP2023519974A (https=) |
| KR (1) | KR20230051120A (https=) |
| CN (1) | CN115867322A (https=) |
| AU (1) | AU2021249532A1 (https=) |
| BR (1) | BR112022019532A2 (https=) |
| CA (1) | CA3173118A1 (https=) |
| IL (1) | IL296846A (https=) |
| MX (1) | MX2022011825A (https=) |
| WO (1) | WO2021198965A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021069705A1 (en) * | 2019-10-09 | 2021-04-15 | Monte Rosa Therapeutics | Isoindolinone compounds |
| BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
| AU2022284372A1 (en) * | 2021-06-03 | 2023-12-14 | Bristol-Myers Squibb Company | Neodegrader-anti-cd33 antibody conjugates |
| IL308811A (en) * | 2021-06-03 | 2024-01-01 | Orum Therapeutics Inc | NEODEGRADER clamps |
| AU2023230346A1 (en) * | 2022-03-09 | 2024-10-17 | Orum Therapeutics, Inc. | Activators of effector t cells |
| CN119212733A (zh) | 2022-05-18 | 2024-12-27 | 苏州宜联生物医药有限公司 | 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途 |
| CN115636811A (zh) * | 2022-08-17 | 2023-01-24 | 成都分迪药业有限公司 | 异吲哚啉苄胺衍生物的合成方法 |
| EP4598587A1 (en) * | 2022-10-06 | 2025-08-13 | Orum Therapeutics Inc. | Neodegrader conjugates |
| EP4667463A1 (en) | 2023-02-15 | 2025-12-24 | CSPC Megalith Biopharmaceutical Co., Ltd. | Domide molecular glue derivative and use thereof |
| WO2024187006A1 (en) * | 2023-03-08 | 2024-09-12 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Bioorthogonal activation of protac prodrugs |
| KR20250169306A (ko) | 2023-04-18 | 2025-12-02 | 아스트라제네카 아베 | 절단가능한 링커를 포함하는 접합체 |
| WO2024222841A1 (zh) * | 2023-04-27 | 2024-10-31 | 石药集团巨石生物制药有限公司 | 一种抗体药物偶联物 |
| AU2024263367A1 (en) | 2023-04-27 | 2025-11-13 | CSPC Megalith Biopharmaceutical Co., Ltd. | Antibody-drug conjugate |
| EP4713023A2 (en) * | 2023-05-18 | 2026-03-25 | Firefly Bio, Inc. | Isoindolinone-glutarimide antibody conjugates, and uses thereof |
| EP4512427A1 (en) * | 2023-08-25 | 2025-02-26 | Mablink Bioscience | Antibody-drug conjugates based on molecular glue degraders and uses thereof |
| WO2025168071A1 (zh) * | 2024-02-08 | 2025-08-14 | 映恩生物制药（苏州）有限公司 | 一种含氮杂环化合物、其偶联物及其制备方法和用途 |
| WO2025252247A1 (zh) * | 2024-06-07 | 2025-12-11 | 上海齐鲁制药研究中心有限公司 | Gspt1降解剂抗体偶联物 |
| WO2026007898A1 (zh) * | 2024-07-01 | 2026-01-08 | 上海海雁医药科技有限公司 | 含苯乙氧基亚烷基胺结构的异吲哚啉化合物、其药物组合物及应用 |
| WO2026032417A1 (zh) * | 2024-08-08 | 2026-02-12 | 石药集团巨石生物制药有限公司 | Gspt1降解剂和含有gspt1降解剂的抗体偶联物及其用途 |
| WO2026041050A1 (zh) * | 2024-08-20 | 2026-02-26 | 海思科医药集团股份有限公司 | 一种配体-蛋白降解剂偶联物及其在医药上的应用 |
| WO2026077418A1 (zh) * | 2024-10-11 | 2026-04-16 | 上海海雁医药科技有限公司 | 含苯乙氧基亚烷基胺结构的异吲哚啉化合物及其偶联物和用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US8877780B2 (en) * | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| PT2358697E (pt) * | 2008-10-29 | 2016-02-03 | Celgene Corp | Compostos de isoindolina para utilização no tratamento do cancro |
| US8114621B2 (en) * | 2010-03-12 | 2012-02-14 | Saladax Biomedical Inc. | Lenalidomide and thalidomide immunoassays |
| EP3827836A1 (en) * | 2014-06-27 | 2021-06-02 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| US9499514B2 (en) * | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| CN113209306A (zh) * | 2014-12-09 | 2021-08-06 | 艾伯维公司 | 具有细胞渗透性的bcl-xl抑制剂的抗体药物缀合物 |
| AR113224A1 (es) * | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| CN119405832A (zh) * | 2018-06-01 | 2025-02-11 | 卫材R&D管理有限公司 | 剪接调节抗体-药物缀合物及其使用方法 |
-
2021
- 2021-03-31 BR BR112022019532A patent/BR112022019532A2/pt unknown
- 2021-03-31 CA CA3173118A patent/CA3173118A1/en active Pending
- 2021-03-31 CN CN202180025882.5A patent/CN115867322A/zh active Pending
- 2021-03-31 IL IL296846A patent/IL296846A/en unknown
- 2021-03-31 AU AU2021249532A patent/AU2021249532A1/en active Pending
- 2021-03-31 JP JP2022559578A patent/JP2023519974A/ja active Pending
- 2021-03-31 US US17/995,006 patent/US20230338564A1/en active Pending
- 2021-03-31 MX MX2022011825A patent/MX2022011825A/es unknown
- 2021-03-31 KR KR1020227037931A patent/KR20230051120A/ko active Pending
- 2021-03-31 WO PCT/IB2021/052713 patent/WO2021198965A1/en not_active Ceased
- 2021-03-31 EP EP21779309.0A patent/EP4126067A4/en active Pending
-
2025
- 2025-06-10 JP JP2025096813A patent/JP2025128284A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023519974A5 (https=) | ||
| JP2024533309A5 (https=) | ||
| JP7630190B2 (ja) | Ｃｄ７を標的にするヒト化抗体及びその使用 | |
| WO2021147928A1 (zh) | 包含嵌合抗原受体的免疫细胞及其用途 | |
| JP2022511813A5 (https=) | ||
| JP7590034B2 (ja) | Ｎｋｇ２ａを標的にする抗体及びその使用 | |
| JP2021523192A5 (https=) | ||
| JP2022548796A5 (https=) | ||
| WO2018121605A1 (zh) | 一种多功能蛋白质 | |
| FI4034252T3 (fi) | Saranadomeenin sisältäviä Notch-reseptoreita | |
| WO2021147929A1 (zh) | 多链嵌合抗原受体及其用途 | |
| JP2019502746A5 (https=) | ||
| JPH02501800A (ja) | 組換ｄｎａ産物及び方法 | |
| JP2021534769A5 (https=) | ||
| JP2023546725A5 (https=) | ||
| JP2023513156A5 (https=) | ||
| JP2024525727A5 (https=) | ||
| JP2023550148A5 (https=) | ||
| EP4502159A1 (en) | Engineered immune cell with ciita gene knock-out and use thereof | |
| JP2021505637A5 (https=) | ||
| WO2023207388A1 (zh) | 一种cd7基因被敲除的工程化免疫细胞及其用途 | |
| JP2024511423A5 (https=) | ||
| JP2025503513A5 (https=) | ||
| KR20210098488A (ko) | 글루타민-함유 경쇄 c-말단 연장부를 포함하는 항체, 그의 접합체, 및 방법 및 용도 | |
| RU2024106608A (ru) | Линкеры для применения нагруженного лекарственным средством антитело |